BPM31510IV is also a lead candidate to treat solid tumours such as glioblastoma multiforme and pancreatic cancer.

BPGbio to present novel Huntington's Disease and Alzheimer's Disease research at the Society for Neuroscience 2024 annual meeting.

WALTHAM, MA — A biotech company is leaving Framingham behind for the new Third Avenue life science building in Waltham. BPGbio announced this week that a lease agreement was reached for 70,000 sq.

BPGbio and Joslin Diabetes Center announce Nature Communications publication showing game-changing effects of blue light in ...

BOSTON--(BUSINESS WIRE)--BPGbio, Inc., a pioneering biology-first, AI-powered, clinical-stage biopharma specializing in mitochondrial biology and protein homeostasis, today announced the ...

Boston, Massachusetts Tuesday, October 1, 2024, 14:00 Hrs [IST] ...

BPGbio, Inc., a leading biology-first, AI-powered, clinical stage biopharma focused on mitochondrial biology and protein homeostasis, today announced that researchers will present two posters on ...

Eli Lilly has announced a $4.5bn investment to establish the Lilly Medicine Foundry for drug production and manufacturing ...

Novaliq and Laboratoires Théa have announced approval from the European Commission (EC) for Vevizye (ciclosporin 0.1% eye ...

BPGbio, a pioneering biology-first, AI-powered, clinical-stage biopharma specializing in mitochondrial biology and protein homeostasis, and Joslin Diabetes Center, the world's leading diabetes ...

BPGbio has received a Rare Pediatric Disease Designation from the US Food and Drug Administration (FDA) for BPM31510IV to treat primary coenzyme Q10 deficiency, an ultra-rare mitochondrial disorder.